BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
This is the first reactor barred in Japan under stricter safety protocols adopted after the Fukushima disaster.
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
The Nuclear Regulation Authority at a regular meeting Wednesday announced the Tsuruga No. 2 reactor is 'unfit' as its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback